Comparing the current results to its competitors, Cerevel Therapeutics Holdings Inc reported Revenue decrease in the 1 quarter 2024 year on year by 0 %, slower than the combined decrease of the CERE's competitors by -5.67 %, recorded in the same quarter.
Cerevel Therapeutics Holdings Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 22.32 %
Cerevel Therapeutics Holdings Inc 's Comment on Competition and Industry Peers
We believe that we possess a number of competitive strengths that position
us to become a leading provider of seeds, traits and bioinformatics technologies,
including:
Current Commercial Products with Multiple Advanced Products in Pipeline
Our current commercial products and product pipeline contain numerous traits
and seed products with potential across multiple crops including sorghum, sugarcane
and corn, among others. Moreover, we are focused on crops and traits outside
the primary market areas of major international agrochemical and agricultural
biotechnology corporations.
Leading Platform with Full Agricultural Biotech Seed Company Capabilities
We are an agricultural biotechnology company that uses biotechnology, advanced
plant breeding and genomic technologies to create high value traits and seeds
to produce agricultural crops. Our integrated technology platform delivers a
combination of valuable genetic assets and competencies in genomics and gene
mapping, biotechnology and bioinformatics. Our iCODE technology enables high
throughput genetic testing that can speed up the trait development process.
In addition to possessing the research and development capabilities necessary
to generate new product candidates, we are vertically integrated, which gives
us the ability to bring agricultural biotechnology products to market in select
crops.
Extensive Intellectual Property Portfolio of High Value Traits and Germplasm
We have an extensive intellectual property portfolio of both field-validated
high value traits and germplasm, which includes thousands of specimens and breeding
lines, as well as multiple pools of regionally adapted germplasm spanning multiple
climates. We have extensive filings around unique combinations of gene promotors
and protein coding sequences. Having both germplasm and field-validated trait
portfolios allows us to leverage the synergies created to facilitate innovation
in a way that is not possible with germplasm or traits alone. In our focus geographies,
we believe that we have a significant advantage over new entrants who would
need several generations of germplasm development and/or access to biotech traits
to achieve performance equivalent to our current product portfolio and pipeline.
Multiple Out-Licensing Opportunities
Our biotech traits and core technology platforms provide multiple opportunities
for exclusive or non-exclusive out-licensing, by crop and/or geography and market.
Traits developed through biotechnology, also known as genetic engineering, can
be added to multiple crops with similar effect in most cases. Our strategy is
to focus on genes that have shown large, step increases in performance and whose
benefits are largely maintained across multiple species.
Positioned to Capitalize on Growth of Large End Markets
Our biotechnology platform, which has proven to increase biomass productivity,
raise quality, reduce crop inputs and improve cultivation on marginal land,
has broad application across multiple end markets and crops. Faced with increasing
demand and limited supply in addition to stresses from climate variability and
competition for water resources, growers are seeking to improve crop productivity
through a number of technologies. Agricultural biotechnology has and will continue
to represent a significant source of innovation for increasing crop yields through
improving performance of seeds.
Validated, Robust Bioinformatics Platform
We have established our Persephone bioinformatics software as a preeminent platform
for storing, organizing, accessing and visualizing genetic information, and
have displaced incumbent solutions at major life science companies. The software
includes a number of proprietary data management optimizations to quickly access
and visualize very large datasets. This speed enables more dynamic visualizations,
intuitive discovery and greater insights into genetic information. We believe
that our direct experience using Persephone internally and our ability to continually
develop and launch new versions with additional features and functions will
enable us to further establish our market position in the plant sciences and
expand into new markets, such as biomedical research and diagnostics.
Attractive Business Model
Seed businesses traditionally incur significant research and development expenditures
and have long product development time lines, but benefit from a combination
of high gross margins, low capital expenditure requirements and intellectual
property protection. Once developed, seeds require little physical infrastructure
or production cost to be replicated for sale. Seeds are typically priced, however,
based on a share of the value created to the customer as opposed to their cost
of production. In general, seed costs to growers are a relatively small percentage
of their total production cost, but the performance of those seeds is critical
to the growers’ economics. We believe we can position our business to
take advantage of low production costs relative to the high value of our products
to our customers.
Management Team with Significant Industry Experience
Our management team includes leading scientists and industry experts who have
extensive experience in the field of agricultural biotechnology and possess
a deep understanding of a variety of agricultural and biotechnology businesses,
including the seed industry.
The seed, agricultural biotechnology and genomics industries are rapidly evolving
and new competitors with competing technologies and products are regularly entering
the market. We expect to compete with other providers of seed and vegetative
propagation materials in the market for our crops as well as other developers
of biotech traits, genetic technologies and bioinformatics software. Based on
our experience with customers, we believe the primary competitive factors in
the seed industry are yield, product quality, performance, scale, price, reliable
supply and sustainability. We believe that the competitive factors affecting
the market for our Persephone software include product functionality and features,
performance, price, ease of product implementation and quality of customer support
services. We believe that our products and services currently compete favorably
with respect to such factors. However, we may not be able to maintain our competitive
position against current and potential competitors.
In the seed industry, our principal competitors may include major international
agrochemical and agricultural biotechnology corporations, such as Advanta India
Limited, The Dow Chemical Company, Monsanto Company, Pioneer Hi-Bred (DuPont),
KWS Saat AG and Syngenta AG, all of which have substantially greater resources
to dedicate to research and development, production or marketing than we have
and some of which are selling competitive products in our markets. We also face
direct competition from other seed companies, such as Chromatin, Inc., S&W
Seed Company and Winfield Solutions LLC, a subsidiary of Land O’ Lakes,
as well as biotechnology companies, and from academic and government research
institutions. In the genomics and bioinformatics market, we face direct competition
from academic and government-funded research institutions as well as commercial
software developers. In addition, well established companies, such as Illumina,
Inc., F.Hoffmann-La Roche Ltd. and Google Inc., may expand the scope of their
current analytical software and services to include visualization and exploration
functions and features similar to Persephone. We are unable to predict what
effect evolution of these industries and potential new entrants may have on
price, selling strategies, intellectual property or our competitive position.
Publicly Traded Peers of Cerevel Therapeutics Holdings Inc
Gossamer Bio Inc Share Performance
+5,764.41%
This Quarter
Gossamer Bio Inc
Profile
Gossamer Bio Inc operates with a business model focused on the development and commercialization of novel therapies for patients with complex diseases. They leverage extensive scientific expertise and strategic partnerships to identify and advance a diverse pipeline of innovative medicines. Their goal is to deliver transformative therapies that address significant unmet medical needs and improve patient outcomes.
Alterity Therapeutics Limited's business model focuses on the development of innovative therapies to treat neurodegenerative diseases, with a special emphasis on Parkinson's disease and Alzheimer's disease.
Acelyrin Inc is a technology company that focuses on providing cutting-edge solutions in the healthcare industry. Their business model is centered around developing innovative software and hardware products that improve patient outcomes, enhance operational efficiency, and drive cost savings for healthcare organizations. By offering a range of advanced tools and services, Acelyrin Inc aims to revolutionize the healthcare sector and contribute to the overall advancement of digital health.
Dianthus Therapeutics Inc is a biotechnology company that focuses on developing novel genetic medicines for patients suffering from rare genetic diseases. Their business model revolves around leveraging cutting-edge gene therapy technologies to design and deliver innovative treatments. By partnering with academic institutions and utilizing a proprietary gene therapy platform, they aim to address unmet medical needs and provide potential new therapies for patients with genetic disorders.
Sources:
Cerevel Therapeutics Holdings Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Cerevel Therapeutics Holdings Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.